Floatz logo

Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)

Urothelial Carcinoma

Vasgene Therapeutics, Incantibody_drug_conjugatePhase 2/3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

162 Active assets in the Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
Cis-Diamminedichloroplatinum Ii
Nagoya University
Phase 3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) is also rated in:

urinary bladder neoplasmActive
BB
Indicative · Phase 2
68 / 100
View asset →
ureter neoplasmActive
BB
Indicative · Phase 2
68 / 100
View asset →
renal pelvis/ureter urothelial carcinomaActive
BB
Indicative · Phase 2
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →